Taysha Gene Therapies, Inc. (TSHA)
- Sector
- Biotechnology
- Last price
- $4.00
- As of
Kresmion compiles this page from TSHA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Taysha Gene Therapies, Inc. (TSHA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-12.
See the full TSHA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TSHA on one page. Preview it with sample data, then open it live with a free account.
Preview the TSHA dossierActive events for TSHA
- mediumEarnings above estimates
Q3-2026: Beat consensus by 24.6%, EPS $-0.10 vs $-0.1326 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +1772% to TSHA (2026Q2)
- high13F: large reduction
TWO SIGMA INVESTMENTS, LP cut 68% of TSHA (2026Q2)
- mediumEarnings below estimates
Q2-2026: Missed consensus by 9.3%, EPS $-0.13 vs $-0.1189 estimate
FREE, NO ACCOUNT
Every event on TSHA, as it fires
New filings, 13F moves and cross asset events on TSHA land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, TSHA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on TSHA
TSHA against its peers
TSHA's operating margin of -1130.6% ranks in the 38th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | TSHA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.8M USD | 67.7M USD | 38 | 11 |
| Gross margin | n/a | 90.9% | n/a | 6 |
| Operating margin | -1130.6% | -239.8% | 38 | 11 |
| Net margin | -1115.3% | -170.1% | 38 | 11 |
| Return on equity | -44.1% | -38.8% | 47 | 15 |
| 1 year | 1.2% | 19.7% | 38 | 19 |
Peers (20): URGN, GHRS, INBX, ABSI, DMRA, LBRX, MLYS, NTLA, MNKD, KRSA, ANAB, NVAX, SLN, VOR, IMCR, TYRA, CMPS, RAPP, SLS, QURE. Left out: AVLN (no annual filing), AAPG (period gap), KALV.D (no annual filing), KARD (no annual filing), ADRX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TSHA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in TSHA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TSHA in the last 180 days.
Upstream: SEC EDGAR filings for TSHA
Kresmion, "Taysha Gene Therapies, Inc. (TSHA) institutional holdings and SEC filings", data as of 2026-11-14, https://kresmion.com/research/TSHA. Upstream data: SEC EDGAR filings for TSHA.
Link to this data (HTML):
<a href="https://kresmion.com/research/TSHA">Taysha Gene Therapies, Inc. (TSHA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow TSHA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TSHA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.